Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

Evaluation of a new lithium colorimetric assay performed on the Dade Behring Dimension® X-pand™ system

  • Damien Gruson , Abdelkrim Lallali , Valérie Furlan , Anne Marie Taburet , Alain Legrand and Marc Conti

Abstract

Lithium is the standard first line of treatment for bipolar disorder. Because of its potential toxicity, levels of the drug have to be constantly monitored. To this end, an accurate and rapid assay is thus required. Moreover, lithium measurement allows differential diagnosis in patients with hallucinations, dementia and amnesia. The lithium concentration in blood is usually evaluated by flame photometry, atomic absorption spectroscopy or ion selective electrode. The aim of this study was to evaluate the analytical performance of a new colorimetric assay for lithium. Within-day precision of a pool with a target value of 1.25 mmol/l was 2.18% (CV) and day-to-day precision was assessed using serum aliquots containing two concentrations of lithium, and CVs were 5.47 and 1.6% at 0.6 and 1.15 mmol/l, respectively. The lower detection limit (LLD) was <0.08 mmol/l. The assay seemed to be linear up to 5 mmol/l. Results of a comparison method using Deming regression were: y=1.161x–0.0075 (r=0.9879) for regression with the Flame Photometer and y=0.9729 x+0.0133 (r=0.9787) for regression with atomic absorption spectroscopy. Moreover, in this study we did not find any interference with drugs or other analytes tested. In conclusion, this assay may be a method of choice for measuring lithium blood concentrations, especially in emergency situations.

Keywords: automation; lithium

Corresponding author: Marc Conti, Laboratoire de Biochimie 1, C.H.U de Bicêtre, AP-HP, 78 Avenue du général Leclerc, 94270 Le Kremlin Bicêtre, France. Phone: + 33 1 45 21 35 67, Fax: + 33 1 45 21 35 74, E-mail:

References

1 Amidisen A. Serum level monitoring and clinical pharmacokinetics of lithium. Clin Pharmacokinet 1977; 2:73–92.10.2165/00003088-197702020-00001Search in Google Scholar

2 Movig KL, Baumgarten R, Leufkens HG, van Laarhoven JH, Egberts AC. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry 2003; 182:319–21.10.1192/bjp.182.4.319Search in Google Scholar

3 Bartha L, Marksteiner J, Bauer G, Benke T. Persistent cognitive deficits associated with lithium intoxication: a neuropsychological case description. Cortex 2002; 38:743–52.10.1016/S0010-9452(08)70041-8Search in Google Scholar

4 Presne C, Fakhouri F, Kenouch S, Stengel B, Kreis H, Grunfeld JP. Progressive renal failure caused by lithium nephropathy [French]. Presse Med 2002; 31:828–33.Search in Google Scholar

5 Christenson RH, Mandichak JJ, Duh SH, Augustyn JM, Thompson JC. Clinical performance characteristics of a new photometric lithium assay: a multicenter study. Clin Chim Acta 2003; 327:157–64.10.1016/S0009-8981(02)00367-4Search in Google Scholar

6 Lobeck F, Nelson MV, Evans RL, Hornstra RK. Evaluation of four methods for predicting lithium dosage. Clin Pharm 1987; 6:230–3.Search in Google Scholar

7 Lobeck F. A review of lithium dosing methods. Pharmacotherapy 1988; 8:248–55.10.1002/j.1875-9114.1988.tb04080.xSearch in Google Scholar PubMed

8 Amdisen A. Monitoring of lithium treatment through determination of lithium concentration. Dan Med Bull 1975; 22:277–91.Search in Google Scholar

Received: 2004-2-10
Accepted: 2004-6-28
Published Online: 2011-9-21
Published in Print: 2004-9-1

© Walter de Gruyter

Downloaded on 5.3.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2004.214/html
Scroll to top button